已收盤 08-07 16:00:00 美东时间
+8.250
+16.92%
Fluor Corporation (NYSE:FLR) shares surged Friday after the engineering and construction company reported second-quarter results that topped Wall Street estimates, driven by strong project execution and a sharp increase in new awards. Adjusted earnings of 91 cents per share beat the analyst consensu...
08-08 01:01
Fluor shares are trading higher after the company reported better-than-expected Q2 financial results.
08-07 19:45
华盛资讯8月7日讯,福陆公布2026财年Q2业绩,公司Q2营收43.29亿美元,同比增长8.8%,归母净利润1.14亿美元,同比下滑95.4%。
08-07 19:22
华盛资讯8月7日讯,福陆公布2026财年Q2业绩,公司Q2营收43.29亿美元,同比增长8.8%,归母净利润1.14亿美元,同比下滑95.4%。
08-07 19:04
Fluor (NYSE:FLR) reported quarterly earnings of $0.91 per share which beat the analyst consensus estimate of $0.70 by 30 percent. This is a 111.63 percent increase over earnings of $0.43 per share from the same period last year. The company reported quarterly sales of $4.329 billion which beat the a...
08-07 18:30
The CNN Money Fear and Greed index showed a slight change in the overall market sentiment, while the index remained in the “Greed” zone on Thursday. U.S. stocks settled mostly lower on Thursday, with the Dow Jones index falling more than 450 points, ending a 5-session win streak amid a surge in crud...
08-07 15:53
With U.S. stock futures trading mixed this morning on Friday, some of the stocks that may grab investor focus today are as follows: Wall Street expects Take-Two Interactive Software Inc. (NASDAQ:TTWO) to post quarterly earnings of 33 cents per share on revenue of $1.41 billion before the opening bel...
08-07 14:55
Fluor Corporation (NYSE:FLR) will release its second quarter earnings report before the opening bell on Friday, Aug. 7. Analysts expect the Irving, Texas-based company to report quarterly earnings of 70 cents per share, up from 43 cents per share in the year-ago period. The consensus estimate for Fl...
08-07 14:50
经济观察网 福陆(FLR)于7月21日拿下巴林GPIC年产120万吨PX+50万吨苯项目的前端设计(FEED)合同,巩固其中东FEED/EPC领域竞争力。 合同...
08-04 03:58
Radiopharm Theranostics reported positive Phase 2b results for imaging agent RAD 101, with 93% of evaluable patients achieving the primary endpoint. The company plans to initiate a Phase 3 registrational trial for RAD 101 in Q4 2026. Additionally, the company raised approximately $12.5 million through an institutional offer and launched a $6 million Share Purchase Plan. RAD 204 showed promising early clinical signs in a Phase 1 trial, with the fi...
07-31 11:00